{"id":49182,"date":"2025-11-27T21:31:35","date_gmt":"2025-11-27T13:31:35","guid":{"rendered":"https:\/\/flcube.com\/?p=49182"},"modified":"2025-11-27T21:31:36","modified_gmt":"2025-11-27T13:31:36","slug":"novo-nordisks-semaglutide-7-2-mg-snda-submitted-for-weight-management","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49182","title":{"rendered":"Novo Nordisk&#8217;s Semaglutide 7.2 mg sNDA Submitted for Weight Management"},"content":{"rendered":"\n<p><strong>Novo Nordisk A\/S<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) announced the submission of a <strong>supplemental New Drug Application (sNDA)<\/strong> to the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for <strong>semaglutide injection 7.2 mg<\/strong> (Wegovy) for chronic weight management in adults with obesity, included in the <strong>CNPV (Expedited Review) program<\/strong> with a <strong>1\u20112 month review timeline<\/strong> expected upon FDA acceptance.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-submission-details\">Regulatory Submission Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Semaglutide injection 7.2 mg (Wegovy)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Novo Nordisk (NYSE: NVO)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Submission Type<\/strong><\/td><td>Supplemental New Drug Application (sNDA)<\/td><\/tr><tr><td><strong>Review Path<\/strong><\/td><td>CNPV (Expedited Review) program<\/td><\/tr><tr><td><strong>Expected Timeline<\/strong><\/td><td>1\u20112 months post\u2011acceptance<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Chronic weight management (adults with obesity)<\/td><\/tr><tr><td><strong>Diet\/Exercise<\/strong><\/td><td>To be used with reduced\u2011calorie diet and increased physical activity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-amp-safety-profile\">Clinical &amp; Safety Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacy:<\/strong> Higher dose intended for enhanced weight loss vs. approved 2.4 mg formulation<\/li>\n\n\n\n<li><strong>Safety Summary:<\/strong><\/li>\n\n\n\n<li><strong>Gastrointestinal adverse events<\/strong> more frequent vs. 2.4 mg and placebo<\/li>\n\n\n\n<li><strong>Dysaesthesia (altered sensation\/paresthesia)<\/strong> reported more commonly<\/li>\n\n\n\n<li><strong>Serious Adverse Events (SAEs):<\/strong> 6.8% (7.2 mg) vs. 10.9% (2.4 mg) vs. 5.5% (placebo)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-regulatory-status\">Global Regulatory Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Status<\/th><th>Expected Decision<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>sNDA submitted; CNPV review<\/td><td>Q1\u202f2026<\/td><\/tr><tr><td><strong>European Union<\/strong><\/td><td>Under review<\/td><td>Q1\u202f2026<\/td><\/tr><tr><td><strong>United Kingdom<\/strong><\/td><td>Under review<\/td><td>H1\u202f2026<\/td><\/tr><tr><td><strong>Other Countries<\/strong><\/td><td>Multiple filings ongoing<\/td><td>TBD<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Obesity Market<\/strong><\/td><td>$12.4\u202fbillion (2024)<\/td><\/tr><tr><td><strong>GLP\u20111 RA Market Share<\/strong><\/td><td>Novo Nordisk <strong>42%<\/strong>, Eli Lilly <strong>38%<\/strong><\/td><\/tr><tr><td><strong>Wegovy 2.4 mg Sales (2024)<\/strong><\/td><td>$4.5\u202fbillion<\/td><\/tr><tr><td><strong>Peak Sales Forecast (7.2 mg)<\/strong><\/td><td><strong>$2.5\u20113.5\u202fbillion<\/strong> incremental by 2028<\/td><\/tr><tr><td><strong>Pricing Strategy<\/strong><\/td><td>Premium to 2.4 mg; expected $1,200\u20111,400\/month<\/td><\/tr><tr><td><strong>Market Share Target<\/strong><\/td><td>15\u201120% of high\u2011BMI patients requiring intensified therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Edge:<\/strong> Higher dose addresses <strong>weight loss plateaus<\/strong> in ~30% of patients; maintains Novo\u2019s innovation leadership vs. Eli Lilly\u2019s Zepbound<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Despite higher GI events, <strong>SAE rate lower than 2.4 mg<\/strong> suggests manageable tolerability<\/li>\n\n\n\n<li><strong>Next Catalyst:<\/strong> FDA approval decision expected <strong>January\u202f2026<\/strong>; EU CHMP opinion <strong>February\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding semaglutide 7.2 mg\u2019s regulatory timeline, commercial potential, and market impact. Actual results may differ materially due to risks including FDA review outcomes, safety concerns, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk A\/S (NYSE: NVO) announced the submission of a supplemental New Drug Application (sNDA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49183,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4361,38,4445,148,860,86],"class_list":["post-49182","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hot-targets","tag-market-approval-filings","tag-metabolic-disease","tag-novo-nordisk","tag-nyse-nvo","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk&#039;s Semaglutide 7.2 mg sNDA Submitted for Weight Management - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for semaglutide injection 7.2 mg (Wegovy) for chronic weight management in adults with obesity, included in the CNPV (Expedited Review) program with a 1\u20112 month review timeline expected upon FDA acceptance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49182\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk&#039;s Semaglutide 7.2 mg sNDA Submitted for Weight Management\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for semaglutide injection 7.2 mg (Wegovy) for chronic weight management in adults with obesity, included in the CNPV (Expedited Review) program with a 1\u20112 month review timeline expected upon FDA acceptance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49182\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-27T13:31:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-27T13:31:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2705.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49182#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49182\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk&#8217;s Semaglutide 7.2 mg sNDA Submitted for Weight Management\",\"datePublished\":\"2025-11-27T13:31:35+00:00\",\"dateModified\":\"2025-11-27T13:31:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49182\"},\"wordCount\":331,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49182#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2705.webp\",\"keywords\":[\"Hot targets\",\"Market approval filings\",\"Metabolic disease\",\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49182#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49182\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49182\",\"name\":\"Novo Nordisk's Semaglutide 7.2 mg sNDA Submitted for Weight Management - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49182#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49182#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2705.webp\",\"datePublished\":\"2025-11-27T13:31:35+00:00\",\"dateModified\":\"2025-11-27T13:31:36+00:00\",\"description\":\"Novo Nordisk A\\\/S (NYSE: NVO) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for semaglutide injection 7.2 mg (Wegovy) for chronic weight management in adults with obesity, included in the CNPV (Expedited Review) program with a 1\u20112 month review timeline expected upon FDA acceptance.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49182#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49182\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49182#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2705.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2705.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk's Semaglutide 7.2 mg sNDA Submitted for Weight Management\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49182#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk&#8217;s Semaglutide 7.2 mg sNDA Submitted for Weight Management\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk's Semaglutide 7.2 mg sNDA Submitted for Weight Management - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk A\/S (NYSE: NVO) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for semaglutide injection 7.2 mg (Wegovy) for chronic weight management in adults with obesity, included in the CNPV (Expedited Review) program with a 1\u20112 month review timeline expected upon FDA acceptance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49182","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk's Semaglutide 7.2 mg sNDA Submitted for Weight Management","og_description":"Novo Nordisk A\/S (NYSE: NVO) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for semaglutide injection 7.2 mg (Wegovy) for chronic weight management in adults with obesity, included in the CNPV (Expedited Review) program with a 1\u20112 month review timeline expected upon FDA acceptance.","og_url":"https:\/\/flcube.com\/?p=49182","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-27T13:31:35+00:00","article_modified_time":"2025-11-27T13:31:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2705.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49182#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49182"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk&#8217;s Semaglutide 7.2 mg sNDA Submitted for Weight Management","datePublished":"2025-11-27T13:31:35+00:00","dateModified":"2025-11-27T13:31:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49182"},"wordCount":331,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49182#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2705.webp","keywords":["Hot targets","Market approval filings","Metabolic disease","Novo Nordisk","NYSE: NVO","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49182#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49182","url":"https:\/\/flcube.com\/?p=49182","name":"Novo Nordisk's Semaglutide 7.2 mg sNDA Submitted for Weight Management - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49182#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49182#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2705.webp","datePublished":"2025-11-27T13:31:35+00:00","dateModified":"2025-11-27T13:31:36+00:00","description":"Novo Nordisk A\/S (NYSE: NVO) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for semaglutide injection 7.2 mg (Wegovy) for chronic weight management in adults with obesity, included in the CNPV (Expedited Review) program with a 1\u20112 month review timeline expected upon FDA acceptance.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49182#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49182"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49182#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2705.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2705.webp","width":1080,"height":608,"caption":"Novo Nordisk's Semaglutide 7.2 mg sNDA Submitted for Weight Management"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49182#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk&#8217;s Semaglutide 7.2 mg sNDA Submitted for Weight Management"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2705.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49182"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49182\/revisions"}],"predecessor-version":[{"id":49184,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49182\/revisions\/49184"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49183"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}